Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis
Authors
Keywords
-
Journal
Immunotherapy
Volume 7, Issue 9, Pages 1023-1037
Publisher
Future Medicine Ltd
Online
2015-06-09
DOI
10.2217/imt.15.50
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Development in Psoriasis
- (2016) Jeffrey M. Sobell et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17
- (2015) Lynda Grine et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes
- (2015) Denis Jullien et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-17–targeting biologics aim to become standard of care in psoriasis
- (2015) Mark Ratner NATURE BIOTECHNOLOGY
- Anti-IL-17 phase II data for psoriasis: A review
- (2014) Gabrielle Brown et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
- (2014) Kenneth B. Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis
- (2014) P. Cordiali-Fei et al. MEDIATORS OF INFLAMMATION
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biological drugs for the treatment of psoriasis in a public health system
- (2014) Luciane Cruz Lopes et al. REVISTA DE SAUDE PUBLICA
- Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity
- (2014) Aikaterini Kyriakou et al. Journal of Immunology Research
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
- (2013) K.B. Gordon et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-17 targeted therapies for psoriasis
- (2013) Andrea Chiricozzi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis
- (2013) Bruce W. Kirkham et al. IMMUNOLOGY
- The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions
- (2013) L. Adelzadeh et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
- (2012) P. Rich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
- (2012) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial
- (2012) Kim A. Papp et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-17C regulates the innate immune function of epithelial cells in an autocrine manner
- (2011) Vladimir Ramirez-Carrozzi et al. NATURE IMMUNOLOGY
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004
- (2008) Shanu Kohli Kurd et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More